Analytical range LOQ [Bioanalytics]

posted by Farmacevt – North Macedonia, 2021-12-22 23:02 (407 d 18:51 ago) – Posting: # 22711
Views: 1,108

But when you say:

❝ At one extreme you may need to eliminate those subject periods that are affected, which may mean a complete loss of a subject for stats if this is a 222BE design, since only subjects who contribute with T and R should be in the stats analysis.

What is the rational for eliminating those subjects? According to my opinion excluding these subjects can not show that the subjects might have had pre-dose concentration below the LOQ with the given method. It will only reduce the power of the study, isn't it?

Edit: Standard quotes restored; see also this post #8[Helmut]

Complete thread:

UA Flag
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
14 visitors (0 registered, 14 guests [including 10 identified bots]).
Forum time: 17:54 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz